{
    "id": "2015eed8-ba87-4994-8787-6b91bf6ff95d",
    "indications": {
        "text": "jardiance indicated : \u2022to reduce risk cardiovascular death hospitalization heart failure adults heart failure . \u2022 reduce risk sustained decline egfr , end-stage kidney disease , cardiovascular death , hospitalization adults chronic kidney disease risk progression . \u2022to reduce risk cardiovascular death adults type 2 diabetes mellitus established cardiovascular disease . \u2022 adjunct diet exercise improve glycemic control adults pediatric patients aged 10 years older type 2 diabetes mellitus .",
        "doid_entities": [
            {
                "text": "end-stage kidney disease (DOID:783)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_783"
            },
            {
                "text": "kidney disease (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "chronic kidney disease (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic kidney disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_133"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 assess renal function initiating clinically indicated . assess volume status correct volume depletion initiating . ( 2.1 ) \u2022 recommended 10 mg orally daily morning , taken without food . ( 2.2 ) \u2022 additional glycemic control , may increased 25 mg orally daily patients tolerating jardiance . ( 2.2 ) \u2022 withhold jardiance least 3 days , possible , prior major surgery procedures associated prolonged fasting . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "jardiance tablets available follows : 10 mg tablets : pale yellow , round , biconvex , bevel-edged film-coated tablets debossed `` 10 `` one side boehringer ingelheim company symbol side . bottles approximately 720 film-coated tablets , ndc 55154-0411-8 25 mg tablets : pale yellow , oval , biconvex film-coated tablets , debossed `` 25 `` one side boehringer ingelheim company symbol side . bottles approximately 990 film-coated tablets , ndc 55154-0412-8 dispense well-closed container defined usp .",
    "adverseReactions": "jardiance contraindicated patients : \u2022with hypersensitivity empagliflozin excipients jardiance , angioedema occurred [ ( 5.8 ) ] .",
    "ingredients": [
        {
            "name": "EMPAGLIFLOZIN",
            "code": "HDC1R2M35U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82720"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Cardinal Health 107, LLC",
    "name": "Jardiance",
    "effectiveTime": "20250430",
    "indications_original": "JARDIANCE is indicated:\n                  \n                     \n                        \u2022to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.\n                     \n                        \u2022\n                        to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.\n                     \n                     \n                        \u2022to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.\n                     \n                        \u2022\n                        as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.",
    "contraindications_original": "\u2022 Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) \u2022 Recommended dosage is 10 mg orally once daily in the morning, taken with or without food. ( 2.2 ) \u2022 For additional glycemic control, dosage may be increased to 25 mg orally once daily in patients tolerating JARDIANCE. ( 2.2 ) \u2022 Withhold JARDIANCE for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting. ( 2.4 )",
    "warningsAndPrecautions_original": "JARDIANCE tablets are available as follows:\n                  \n                     10 mg tablets: pale yellow, round, biconvex, and bevel-edged film-coated tablets debossed with \"S 10\" on one side and the Boehringer Ingelheim company symbol on the other side. \n                  Bottles of approximately 720 film-coated tablets, NDC 55154-0411-8\n                  \n                     25 mg tablets: pale yellow, oval, biconvex film-coated tablets, debossed with \"S 25\" on one side and the Boehringer Ingelheim company symbol on the other side. \n                  Bottles of approximately 990 film-coated tablets, NDC 55154-0412-8\n                  Dispense in a well-closed container as defined in the USP.",
    "adverseReactions_original": "JARDIANCE is contraindicated in patients:\n                  \n                     \n                        \u2022with a hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred [see Warnings and Precautions (5.8)].",
    "drug": [
        {
            "name": "Jardiance",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82720"
        }
    ]
}